HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Reversible posterior leukoencephalopathy syndrome (RPLS) in a heart transplant recipient treated by substitution of cyclosporine A with tacrolimus.

Abstract
Reversible posterior leukoencephalopathy syndrome (RPLS) is one of the important adverse events following organ transplantation, associated with calcineurin inhibitors (CNIs). We describe a case of 54-year-old woman, who was diagnosed with RPLS within weeks after transplantation. Considering the risk of causing fatal rejection by discontinuation of CNIs, the immunosuppressive regimen of the patient was switched from a cyclosporine A-based regimen to a tacrolimus-based regimen. The patient recovered rapidly from RPLS following the switch to tacrolimus. This case demonstrated that not only discontinuation but also a substitution of CNIs would be a valid treatment option for RPLS in transplant recipients.
AuthorsNoboru Oda, Tomoko S Kato, Akihisa Hanatani, Kazuo Niwaya, Takeshi Nakatani, Hatsue Ishibashi-Ueda, Soichiro Kitamura, Kazuhiko Hashimura, Masafumi Kitakaze, Kazuo Komamura
JournalInternal medicine (Tokyo, Japan) (Intern Med) Vol. 49 Issue 11 Pg. 1013-6 ( 2010) ISSN: 1349-7235 [Electronic] Japan
PMID20519818 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Cyclosporine
  • Tacrolimus
Topics
  • Cyclosporine (administration & dosage, adverse effects)
  • Female
  • Graft Rejection (drug therapy)
  • Heart Transplantation (adverse effects)
  • Humans
  • Middle Aged
  • Posterior Leukoencephalopathy Syndrome (chemically induced, diagnosis, etiology)
  • Tacrolimus (administration & dosage)
  • Transplantation (adverse effects)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: